Published in NMR Biomed on January 26, 2012
Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis. Proc Natl Acad Sci U S A (2012) 1.41
Cellular and physiological roles for phospholipase D1 in cancer. J Biol Chem (2014) 0.91
Interplay of choline metabolites and genes in patient-derived breast cancer xenografts. Breast Cancer Res (2014) 0.91
Choline-releasing glycerophosphodiesterase EDI3 links the tumor metabolome to signaling network activities. Cell Cycle (2012) 0.86
EDI3 links choline metabolism to integrin expression, cell adhesion and spreading. Cell Adh Migr (2014) 0.84
Choline metabolism-based molecular diagnosis of cancer: an update. Expert Rev Mol Diagn (2015) 0.81
Metabolic Portraits of Breast Cancer by HR MAS MR Spectroscopy of Intact Tissue Samples. Metabolites (2017) 0.80
Glycerophosphoglycerol, Beta-alanine, and pantothenic Acid as metabolic companions of glycolytic activity and cell migration in breast cancer cell lines. Metabolites (2013) 0.80
Breast Tissue Metabolism by Magnetic Resonance Spectroscopy. Metabolites (2017) 0.79
The effect of antitumor glycosides on glioma cells and tissues as studied by proton HR-MAS NMR spectroscopy. PLoS One (2013) 0.78
Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. Cancer Metab (2016) 0.77
Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by (31) P MRS. NMR Biomed (2014) 0.77
Targeting Phospholipid Metabolism in Cancer. Front Oncol (2016) 0.77
Increased phosphatidylethanolamine N-methyltransferase gene expression in non-small-cell lung cancer tissue predicts shorter patient survival. Oncol Lett (2014) 0.76
The Tumor Microenvironment Modulates Choline and Lipid Metabolism. Front Oncol (2016) 0.75
Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer. Front Oncol (2016) 0.75
Molecular Effects of Doxorubicin on Choline Metabolism in Breast Cancer. Neoplasia (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Mammalian MAP kinase signalling cascades. Nature (2001) 18.89
Tamoxifen in the treatment of breast cancer. N Engl J Med (1998) 4.75
Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol (2011) 3.73
Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res (1999) 3.23
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res (2004) 2.43
Phospholipase D in cell proliferation and cancer. Mol Cancer Res (2003) 2.13
Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res (2005) 2.11
Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun (2002) 2.09
Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene (2002) 2.09
Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. Radiology (2004) 1.95
RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res (2005) 1.77
Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer (2007) 1.72
Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia (2004) 1.70
Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res (2010) 1.65
Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn (2006) 1.54
Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer (2006) 1.54
Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res (2004) 1.53
Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst (2002) 1.51
Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res (1996) 1.42
Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res (2002) 1.40
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res (2006) 1.29
Transmembrane protein GDE2 induces motor neuron differentiation in vivo. Science (2005) 1.27
Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res (2009) 1.27
Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed (2010) 1.26
Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med (2008) 1.25
Metabolic tumor imaging using magnetic resonance spectroscopy. Semin Oncol (2011) 1.22
CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One (2008) 1.20
Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J Proteome Res (2010) 1.20
In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res (1999) 1.19
Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene (2002) 1.19
Biochemical and molecular characterization of a novel choline-specific glycerophosphodiester phosphodiesterase belonging to the nucleotide pyrophosphatase/phosphodiesterase family. J Biol Chem (2005) 1.17
Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene (2003) 1.13
GDPD5 is a glycerophosphocholine phosphodiesterase that osmotically regulates the osmoprotective organic osmolyte GPC. Proc Natl Acad Sci U S A (2008) 1.12
1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas. NMR Biomed (2009) 1.11
Accumulation of glycerophosphocholine (GPC) by renal cells: osmotic regulation of GPC:choline phosphodiesterase. Proc Natl Acad Sci U S A (1991) 1.08
Osmoregulation of GPC:choline phosphodiesterase in MDCK cells: different effects of urea and NaCl. Am J Physiol (1995) 1.03
Isolation and characterization of two serpentine membrane proteins containing glycerophosphodiester phosphodiesterase, GDE2 and GDE6. Gene (2004) 1.03
PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas. Br J Cancer (2007) 1.02
Novel membrane protein containing glycerophosphodiester phosphodiesterase motif is transiently expressed during osteoblast differentiation. J Biol Chem (2003) 0.99
Increased choline kinase activity in 1,2-dimethylhydrazine-induced rat colon cancer. Jpn J Cancer Res (1999) 0.99
The developmentally regulated osteoblast phosphodiesterase GDE3 is glycerophosphoinositol-specific and modulates cell growth. J Biol Chem (2009) 0.97
A novel use for the word "trend" in the clinical trial literature. Am J Med Sci (2003) 0.96
Proton MR spectroscopy for monitoring early treatment response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol (2008) 0.96
Touch imprint cytology in tumor tissue banks for the confirmation of neoplastic cellularity and for DNA extraction. Arch Pathol Lab Med (2008) 0.85
Novel ketoepoxides block phospholipase D activation and tumor cell invasion. Anticancer Drug Des (1994) 0.82
Isolation, characterization and molecular 3D model of human GDE4, a novel membrane protein containing glycerophosphodiester phosphodiesterase domain. Mol Membr Biol (2008) 0.82
GDP-bound Galphai2 regulates spinal motor neuron differentiation through interaction with GDE2. Dev Biol (2010) 0.79
Cloning and characterization of a human GDPD domain-containing protein GDPD5. Mol Biol Rep (2007) 0.79
A novel splice variant of human gene GDPD1 is mainly expressed in human ovary and small intestine. Int J Mol Med (2003) 0.77
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med (2004) 10.41
HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell (2007) 6.06
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
Mutation of GATA3 in human breast tumors. Oncogene (2004) 3.92
MRI of the tumor microenvironment. J Magn Reson Imaging (2002) 2.87
Choline metabolism in malignant transformation. Nat Rev Cancer (2011) 2.85
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res (2004) 2.43
Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res (2005) 2.32
Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem (2003) 2.12
Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res (2003) 2.05
High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed (2002) 2.05
Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed (2006) 2.01
OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha. Mol Cell (2005) 1.91
Natural D-glucose as a biodegradable MRI contrast agent for detecting cancer. Magn Reson Med (2012) 1.84
Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells. Am J Pathol (2010) 1.79
RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res (2005) 1.77
MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med (2003) 1.76
Expression of vascular endothelial growth factor receptor 1 in bone marrow-derived mesenchymal cells is dependent on hypoxia-inducible factor 1. J Biol Chem (2006) 1.70
Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia (2004) 1.70
Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med (2008) 1.69
Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res (2005) 1.68
Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res (2010) 1.65
Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol (2010) 1.63
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol (2006) 1.55
Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn (2006) 1.54
Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. Cancer Res (2008) 1.52
Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res (2010) 1.48
Spontaneous transformation of cultured mouse bone marrow-derived stromal cells. Cancer Res (2006) 1.48
Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer (2010) 1.46
Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Res (2006) 1.41
Merging transcriptomics and metabolomics--advances in breast cancer profiling. BMC Cancer (2010) 1.41
Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. Cancer Res (2010) 1.40
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell (2011) 1.40
Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm (2006) 1.37
Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res (2010) 1.32
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol (2011) 1.31
The transcription factor encyclopedia. Genome Biol (2012) 1.28
Self-assembled three dimensional radio frequency (RF) shielded containers for cell encapsulation. Biomed Microdevices (2005) 1.28
Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res (2007) 1.27
Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res (2009) 1.27
Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed (2010) 1.26
MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat (2006) 1.25
Hypoxia regulates CD44 and its variant isoforms through HIF-1α in triple negative breast cancer. PLoS One (2012) 1.25
Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling. NMR Biomed (2011) 1.24
The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A (2011) 1.24
Metabolic tumor imaging using magnetic resonance spectroscopy. Semin Oncol (2011) 1.22
Metabolomics of cancer. Methods Mol Biol (2009) 1.21
Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. J Magn Reson Imaging (2009) 1.19
SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. Eur J Cancer (2011) 1.19
Magnetic resonance imaging of cell surface receptors using targeted contrast agents. Curr Pharm Biotechnol (2004) 1.17
Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by magnetic resonance imaging. Cancer Res (2005) 1.15
Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Mol Cancer Res (2007) 1.14
PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn Reson Med (2008) 1.13
Hypoxic tumor microenvironments reduce collagen I fiber density. Neoplasia (2010) 1.12
MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk. Oncotarget (2011) 1.11
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res (2008) 1.11
Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia (2009) 1.10
Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness. PLoS One (2013) 1.09
Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncol (2005) 1.09
Combined dynamic contrast enhanced breast MR and proton spectroscopic imaging: a feasibility study. J Magn Reson Imaging (2005) 1.08
Collagen I fiber density increases in lymph node positive breast cancers: pilot study. J Biomed Opt (2012) 1.08
Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer. Chem Rev (2010) 1.06
Multimodal mass spectrometric imaging of small molecules reveals distinct spatio-molecular signatures in differentially metastatic breast tumor models. Cancer Res (2010) 1.06
Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS. NMR Biomed (2010) 1.06
Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy. BMC Cancer (2012) 1.05
Mass spectrometry images acylcarnitines, phosphatidylcholines, and sphingomyelin in MDA-MB-231 breast tumor models. J Lipid Res (2012) 1.04
Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients. J Magn Reson Imaging (2011) 1.04
Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. Mol Cancer (2006) 1.04
MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer. NMR Biomed (2011) 1.03
Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells. NMR Biomed (2010) 1.03
Short echo time 1H MRSI of the human brain at 3T with adiabatic slice-selective refocusing pulses; reproducibility and variance in a dual center setting. J Magn Reson Imaging (2010) 1.02
Toward digital staining using imaging mass spectrometry and random forests. J Proteome Res (2009) 1.02
Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts. J Magn Reson Imaging (2013) 1.02
Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line. Neoplasia (2007) 1.02
Expression of DDX3 is directly modulated by hypoxia inducible factor-1 alpha in breast epithelial cells. PLoS One (2011) 1.02
Molecular Imaging of Cancer: Applications of Magnetic Resonance Methods. Proc IEEE Inst Electr Electron Eng (2005) 1.02
Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon. Int J Cancer (2014) 1.01
Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy. ACS Nano (2010) 1.01
Image-guided enzyme/prodrug cancer therapy. Clin Cancer Res (2008) 1.01
Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription (2012) 1.01
Cervical cancer tissue characterized by high-resolution magic angle spinning MR spectroscopy. MAGMA (2004) 1.00
Lymph node metastasis in breast cancer xenografts is associated with increased regions of extravascular drain, lymphatic vessel area, and invasive phenotype. Cancer Res (2006) 1.00
Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration. Neoplasia (2008) 1.00
Molecular-functional imaging of cancer: to image and imagine. Trends Mol Med (2007) 1.00